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Abstract
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organ systems.
Previous studies have suggested that interferon-lambda 1 (IFN-l1), a type III interferon, plays an
immunomodulatory role. In this study we investigated its role in SLE, including its correlation with disease activity,
organ disorder and production of chemokines.
Methods: We determined levels of IFN-l1 mRNA in peripheral blood mononuclear cells (PBMC) and serum protein
levels in patients with SLE using real-time polymerase chain reaction (real-time PCR) and enzyme-linked
immunoassay (ELISA). Further, we detected the concentration of IFN-inducible protein-10 (IP-10), monokine
induced by IFN-g (MIG) and interleukin-8 (IL-8) secreted by PBMC under the stimulation of IFN-l1 using ELISA.
Results: IFN-l1 mRNA and serum protein levels were higher in patients with SLE compared with healthy controls.
Patients with active disease showed higher IFN-l1 mRNA and serum protein levels compared with those with
inactive disease as well. Serum IFN-l1 levels were positively correlated with Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI), anti-dsDNA antibody, C-reactive protein (CRP) and negatively correlated with complement
3. Serum IFN-l1 levels were higher in SLE patients with renal involvement and arthritis compared with patients
without the above-mentioned manifestations. IFN-l1 with different concentrations displayed different effects on
the secretion of the chemokines IP-10, MIG and IL-8.
Conclusions: These findings indicate that IFN-l1 is probably involved in the renal disorder and arthritis
progression of SLE and associated with disease activity. Moreover, it probably plays an important role in the
pathogenesis of SLE by stimulating secretion of the chemokines IP-10, MIG and IL-8. Thus, IFN-l1 may provide a
novel research target for the pathogenesis and therapy of SLE.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
and inflammatory disease characterized by the activation
of T and polyclonal B lymphocytes, production of
numerous autoantibodies, and formation of immune
complexes that result in tissue and organ damage [1].
The interferon (IFN) family plays an important role in
innate as well as adaptive immune responses against
viral infections [2]. Classic IFNs include the type I sub-
g r o u pc o m p o s e do fI F N - a,I F N - b,I F N - ω,I F N - ,I F N - τ,
and the type II subgroup represented by IFN-g [3]. Pre-
vious studies have suggested that both subgroups play
an important role in the pathogenesis of SLE [3-6].
Type III IFN, IFN-l1, IFN-l2, IFN-l3, also referred to
as interleukin (IL)-29, IL-28A and IL-28B, respectively, are
novel members of the IFN super-family [7,8]. They are
secreted by human peripheral blood mononuclear cells
(PBMC) as well as dendritic cells (DC) upon infection
with viruses or stimulation with poly (I:C) or lipopolysac-
charide (LPS) [2,8], and express in a broad spectrum of
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any medium, provided the original work is properly cited.tissues [7]. Gene expressions are regulated by virus-acti-
vated interferon regulatory factor (IRF) 3 and IRF 7 [9].
These proteins induce activation of JAK/STAT signaling
pathways through a cell-surface receptor consisting of two
chains, IFN-lR1, which is IFN-l- specific, and IL-10R2,
which is shared among IL-10, IL-22 and IL-26 [10,11].
IFN-l share several common features with type I IFN,
such as antiviral, anti-proliferative as well as antitumor
activities [2,10,12-15], meantime, their immune-regula-
tory function has gradually been elucidated as well.
Recent studies have reported that IFN-l-treated DC
specifically induced proliferation of a CD4+CD25+Foxp3
+T cell subset [16]. IFN-l1 was able to inhibit human
type 2 helper T (Th2) cell responses by diminishing
secretion of IL-13, and also specifically upregulated
cytokines IL-6, IL-8 and IL-10 levels secreted by mono-
cytes in a dose-dependent manner [17-19].
Chemokines are a group of small molecules with the
ability to direct cell movements necessary for the initia-
tion of T cell immune response, recruit specific leuco-
cytes to inflammatory sites, regulate polarization of Th1
and Th2 lymphocytes, and influence maturation of DC,
T cell and bone marrow progenitor [20-23]. Moreover,
they can stimulate monocytes, natural killer (NK) and T
cell migration, and modulate adhesion molecule expan-
sion [24]. Therefore, they are related to tissue inflamma-
tion and organ damage in SLE.
IFN-inducible protein-10 (IP-10) is a CXC chemokine
secreted by PBMC, fibroblasts and endothelial cells [25],
and plays an important role in the perpetuation of
chronic inflammatory responses by promoting the
recruitment of monocytes, Ta n dN Kc e l l si n t ot a r g e t
tissue and organ [26]. IL-8, another CXC chemokine, is
predominantly chemotactic for neutrophils, and also has
the capability of recruiting leukocytes to the glomerulus
during immune renal damage [27].
Many studies have discovered that plasma chemokine
concentrations including IL-8, IP-10 and monokine
induced by IFN-g (MIG) are elevated in patients with
active SLE [28-31]. Some studies have reported that
urinary IL-8 levels are increased in SLE patients with
active renal disease as well [27,32].
With this background, we compared expression of
IFN-l1 mRNA in PBMC and serum protein levels in
SLE patients with healthy controls. In addition, we
determined the correlation of serum IFN-l1 levels with
disease activity and clinical manifestations in SLE, and
investigated the effect of IFN-l1 on the secretion of the
chemokines IP-10, MIG and IL-8.
Materials and methods
Patients and controls individuals
This study was approved by the Review Board for Shan-
dong Provincial Hospital in Jinan, People’s Republic of
China. Informed consent was obtained from all study
participants. A total of 42 patients meeting the revised
American College of Rheumatology criteria for SLE and
25 age-matched and sex-matched healthy controls were
enrolled in the present study. All SLE patients were
recruited from the Rheumatology Department, Provin-
cial Hospital Affiliated to Shandong University, and indi-
viduals with other rheumatic diseases, infections or
m a l i g n a n tt u m o r sw e r ee x c l u d e df r o mt h es t u d y .
Healthy controls were selected from a great many
healthy volunteers at the Provincial Hospital Affiliated
to Shandong University in order to match them to the
SLE patients in terms of age and sex.
SLE patients’ laboratory tests containing anti-double
stranded (ds) DNA antibody, anti-nucleosome antibody
(AnuA), anti-smith-antibody, anti- ribosome ribonucleo-
protein antibody (rRNP), anti-histone antibody (AHA),
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), complement 3 (C3) and C4 as well as 24-hour
urine protein were performed. Clinical data from each
patient were recorded. These were new patients who
were diagnosed with SLE for the first time and needed
to receive steroid therapy with an average prednisone
(or equivalent) dosage of 10 mg/day (median 10 mg,
range 5 to 15 mg) according to their disease condition
at that time. Before their blood samples were prepared,
26 patients had not taken prednisone, and 16 patients
had taken prednisone once. Lupus disease activities
were assessed using the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) score [33]. Active
lupus disease was defined as a SLEDAI score ≥6 [33].
Characteristics of the SLE patients and healthy controls
are listed in Table 1.
Blood samples
Fasting venous blood (4 ml) was collected and processed
within two hours. PBMC were isolated from patients and
healthy controls by density-gradient centrifugation over
‘Histopaque-1077’ (Sigma, St Louis, MO, USA) for cell cul-
ture or stored at -80°C until RNA extraction. Serum sam-
ples were stored at -80°C until cytokine were determined.
RNA extraction
Total RNA was extracted from PBMC with Trizol (Invi-
trogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Then the quantity and purity of RNA
was determined by absorbance on a spectrophotometer
(Beckman Instruments, Fullerton, CA, USA) at 260 nm
and 280 nm. Samples with ratios from 1.8 to 2.0 were
accepted for next reverse transcription reaction.
Reverse transcription reaction
The 20-μl cDNA synthesis reaction was performed with
0.3 μg RNA containing 1 μl of random hexamer
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dNTP mix, and 1 μl of RiboLock ribonuclease inhibitor
(Fermentas, Burlington, Ontario, Canada. Reverse tran-
scription was carried out at 25°C for 10 minutes, 42°C
for 60 minutes, and 70°C for 10 minutes using Gene
Amp PCR system 9700 (Applied Biosystems, Foster
City, CA, USA).
Real-time polymerase chain reaction
The primers were designed by BIOSUNE (Shanghai,
China): IFN-l1 forward primer 5’-TAT CCA GCC TCA
GCC CAC AG-3’, reverse primer 5’-CTC AGA CAC
AGG TTC CCA TCG-3’; b-actin forward primer 5’-
CAC TCT TCC AGC CTT CCT TCC-3’, reverse primer
5’-AGG TCT TTG CGG ATG TCC AC-3’. Real-time
polymerase chain reaction (PCR) amplification reactions
were prepared with the SYBR Green PCR Master Mix
(Applied Biosystems, USA) and performed using the
7500 Real-Time PCR system (Applied Biosystems, USA).
Each 20 μl real-time PCR included 10 μl of SYBR Green
PCR Master Mix, 5 μl of primers (concentrations were
0.2 μmol) and 5 μl of cDNA (after reverse transcription
diluted 1:5 with Diethyl Pyrocarbonate water). PCR con-
ditions consisted of initial denaturation at 95°C for 10
minutes, followed by 40 cycles of denaturation at 95°C
for 15 s, and annealing extension at 60°C for 1 minute.
PCR products were verified by melting curve analysis.
Relative mRNA levels were determined by the 2
-ΔΔct
method.
Cell culture condition
Culture medium, consisted of RPMI 1640 medium
(Hycolne, Logan, UT, USA) supplemented with 10%
Fetal Calf Serum (Gibco-Invitrogen, Mulgrave, Victoria,
Australia), 2 mmol/L L-glutamine, 100 IU/mL penicillin
and 100 μg/mL streptomycin (Sigma, Ronkonkoma, NY,
USA), respectively. Whole PBMC were cultured in 24-
well, flat-bottomed plates (5 × 10
5 i n1m l )f o r7 2h .I n
the PBMC culture system there were different culture
groups: PBMC alone, PBMC were stimulated with LPS
at 100 ng/ml (Sigma, USA), PBMC were stimulated with
human recombinant IFN-l1a t1 0n g / m l ,5 0n g / m l ,1 0 0
ng/ml (Peprotech, Rocky Hill, NJ, USA), respectively,
PBMC were stimulated with LPS at 100 ng/ml in the
presence of human recombinant IFN-l1 at 10 ng/ml, 50
ng/ml and 100 ng/ml, respectively. In the experiment of
observing the synergistic effect of IFN-l1a n dL P S ,
whole PBMC were incubated in the presence of different
concentration of IFN-l1 for 30 minutes before the addi-
tion of LPS.
Supernatants were harvested and froze at -80°C for
later cytokine analysis by ELISA.
Enzyme-linked immunosorbent assay
Serum IFN-l1 levels and cell culture supernatant MIG,
IP-10 and IL-8 levels were determined by enzyme-linked
immunosorbent assay (ELISA) following the manufac-
turer’s instructions. IFN-l1 was quantified using ELISA
reagent kits purchased from Adlitteram Diagnostic
Laboratories (San Diego, CA, USA). Detection of the
chemokines MIG, IP-10 and IL-8 was accomplished
using the Bender MedSystem (Vienna, Austria)
Statistical analysis
Differences in IFN-l1 mRNA expression and serum
protein levels as well as differences of chemokines MIG,
IP-10 and IL-8 levels among the different populations
were determined by Mann-Whitney U-test, one-way
ANOVA with Bonferroni analysis. Spearman correlation
test was used to assess the association between serum
Table 1 Demographics of SLE and healthy controls
SLE patients
(n = 42)
Healthy donors
(n = 25)
Age (years) 27.4 ± 10.12
(13 to 45)
25.2 ± 9.58 (20 to 42)
Sex(female/male) 39/3 23/2
Disease duration(years) 2.45 ± 2.67 -
Alopecia n (%) 16 (38.1) -
Mucosal ulcer n (%) 10 (23.8) -
Malar rash n (%) 26 (61.9) -
Arthritis n (%) 29 (69.1) -
Current renal disease
n (%)
25 (59.5) -
Pleuritis n (%) 2 (4.8) -
Fever n (%) 10 (23.8) -
Neurological disorder
n (%)
2 (4.8) -
Anemia n (%) 12 (28.6) -
Thrombocytopenia n (%) 8 (19) -
Leukopenia n (%) 22 (52.4) -
ds-DNA n (%) 26 (61.9) -
AnuA n (%) 20 (47.6) -
Smith n (%) 10 (23.8) -
AHA n (%) 20 (47.6) -
rRNP n (%) 8 (19)
ESR 34.05 ± 26.79 -
CRP 5.31 ± 6.44 -
Low C3 n (%) 26 (61.9) -
Low C4 n (%) 22 (52.4) -
24-hour urine protein
n (%)
22 (52.4)
(> 0.5 g/24 h)
-
SLEDAI 4 to 30 (13.9 ± 7.12) -
Except where otherwise indicated, values are expressed as mean ± standard
deviation. There were no significant differences between patients with SLE
and healthy donors in terms of age and sex. AHA, anti-histone antibody;
AnuA, anti-nucleosome antibody; C3, complement 3; C4, complement 4; CRP,
C-reactive protein; ds-DNA, anti-double stranded DNA antibody; ESR,
erythrocyte sedimentation rate; rRNP, anti-ribosome ribonucleoprotein
antibody; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity
index; Smith, anti-smith-antibody.
Wu et al. Arthritis Research & Therapy 2011, 13:R88
http://arthritis-research.com/content/13/3/R88
Page 3 of 12IFN-l1 levels and different variables. Analysis was per-
formed with Statistical Package for the Social Science
(SPSS) version 16.0. (SPSS Inc., Chicago, IL, USA). P <
0.05 was considered statistically significant.
Results
IFN-l1 mRNA and serum protein levels were higher in
patients with SLE compared with healthy controls
Initially, the expression of IFN-l1 mRNA in PBMC and
serum IFN-l1 protein levels from 42 SLE patients and
25 normal controls (NC) were measured using real-time
reverse transcription PCR and ELISA, respectively. SLE
patients and normal controls did not reveal significant
differences in terms of mean age or sex distribution
(Table 1). As shown in Figure 1a, SLE patients had sig-
nificantly higher IFN-l1 mRNA level than did normal
controls (P = 0.012). Figure 1b also displayed significant
elevation of serum IFN-l1 protein levels in patients
with SLE compared with normal controls (P = 0.000),
indicating that IFN-l1 probably participated in the
pathogenesis of SLE.
IFN-l1 mRNA and serum protein levels were higher in
SLE patients with active disease compared with those
with inactive disease
We next investigated whether IFN-l1 was related to dis-
ease activity in SLE patients. We divided SLE patients
into active groups (SLEDAI score ≥6) and inactive groups
(SLEDAI score < 6) according to SLEDAI. As seen in Fig-
ure 2a, b, significant differences were viewed in IFN-l1
mRNA and protein levels between patients with active
and those with inactive disease (P < 0.0001, P = 0.028). In
the meantime, patients with active disease displayed
higher IFN-l1 mRNA and serum protein levels com-
pared with normal controls (P < 0.0001, P < 0.0001);
however, we did not observe the differences of IFN-l1
mRNA and protein levels between patients with inactive
disease and normal controls (data not shown). Thus, we
speculated that IFN-l1 probably was associated with dis-
ease activity in SLE.
Correlation between IFN-l1 levels and SLEDAI as well as
laboratory values
To further survey the relationship between serum IFN-
l1 protein levels and disease activity, we next deter-
mined correlations between IFN-l1 and SLEDAI as well
as laboratory values containing anti-dsDNA, AnuA,
smith, rRNP, AHA antibody, ESR, CRP, C3, C4 and 24-
hour urine protein. We surveyed that serum IFN-l1
protein levels were positively correlated with SLEDAI,
anti-dsDNA antibody and CRP (r = 0.4103, P =0 . 0 0 7 ,
Figure 3a; r = 0.8339, P < 0.0001, Figure 3b; r = 0.3760,
P = 0.0141, Figure 3c). There was a negative correlation
between serum IFN-l1 levels and complement C3 (r =
-0.5863, P = 0.008, Figure 3d). No significant correla-
tions were found between serum IFN-l1 levels and anti
-AnuA, smith, rRNP, AHA antibody, ESR, C4 and 24-
hour urine protein (Table 2).
Association of serum IFN-l1 protein levels with clinical
features in SLE
To assess associations between serum IFN-l1p r o t e i n
levels and clinical manifestations, serum IFN-l1p r o t e i n
levels were compared among patients with and those
without certain clinical features as well as normal con-
trols. We identified that no significant differences in
serum IFN-l1 protein levels between patients in the
presence of alopecia, mucosal ulcer, malar rash, chest
affection, fever, neurological disorder, anemia, thrombo-
cytopenia, leucopenia and patients in the absence of the
Figure 1 Comparison of IFNl1 mRNA and protein levels between SLE and NC. The methods employed to detect expression levels of IFNl1
mRNA and protein levels are described in Materials and methods. (a) IFNl1 mRNA levels were significantly elevated in SLE patients versus NC.
(b) Serum IFNl1 protein levels were significantly elevated in SLE patients versus NC. Each symbol represents an individual patient and healthy
donor. Horizontal lines indicate median values. IFNl1, interferon l1; NC, normal control; SLE, systemic lupus erythematosus.
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Page 4 of 12Figure 2 Comparison of IFNl1 mRNA and protein levels among SLE patients with active disease and inactive disease as well as NC.( a)
IFNl1 mRNA levels were significantly elevated in SLE patients with active disease (n = 27) compared with those with inactive disease (n = 15) as
well as NC. (b) Serum IFNl1 protein levels were significantly elevated in SLE patients with active disease compared with those with inactive
disease together with NC. Each symbol represents an individual patient. horizontal lines indicate median values. IFNl1, interferon l1; NC, normal
control; SLE, systemic lupus erythematosus.
Figure 3 Association of serum IFN-l1 levels with SLEDAI as well as laboratory values. Each symbol represents an individual patient. (a)
Serum IFN-l1 levels were positively correlated with SLEDAI. (b) A significantly positive correlation was observed between serum IFN-l1 levels
and anti-dsDNA antibody. (c) Positive correlation was also seen between serum IFN-l1 levels and CRP. (d) Negative relationship was observed
between serum IFN-l1 levels and C3. anti-dsDNA antibody, anti-double stranded DNA antibody; C3, complement 3; CRP, C-reactive protein;
IFNl1, interferon l1; SLEDAI, systemic lupus erythematosus disease activity index.
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Nevertheless, we discerned that serum IFN-l1l e v e l s
were significantly higher in patients with renal disease
and arthritis compared with patients without these man-
ifestations together with normal controls. (P = 0.0368, P
< 0.0001, Figure 4a; P = 0.0097, P = 0.0028, Figure 4b),
meantime, patients in the absence of renal disorder had
higher serum IFN-l1 level compared with normal con-
trols as well (P = 0.0258, Figure 4a), but patients with-
out arthritis did not show significant higher serum IFN-
l1 level than normal controls (data not shown), illus-
trating that IFN-l1 probably acted in the development
of renal disorder and arthritis in SLE.
IFN-l1 induced IP-10, MIG and IL-8 production in PBMC
of SLE patients
Next, we inquired into whether IFN-l1p l a y e dar o l ei n
the secretion of several chemokines involved in the
pathogenesis of SLE. We approached the chemokines pro-
duced by SLE patients PBMC in response to IFN-l1a n d
contrasted it to that obtained following LPS stimulation.
As manifested in Figure 5, in both SLE patients and nor-
mal controls, IFN-l1-stimulated PBMC emerged higher
levels of chemokines IP-10 (P = 0.039, 0.028, Figure 5a)
and MIG (P = 0.009, 0.038, Figure 5b) in comparison with
positive control LPS, and about the secretion of IL-8, the
same result was observed in normal controls (P = 0.049,
Figure 5c). Moreover, at 50 ng/ml IFN-l1, the generation
levels of chemokines IP-10 and MIG in SLE patients were
more than normal controls (P = 0.02, Figure 5a; P =0 . 0 3 1 ,
Figure 5b), and the secretion levels of IL-8 were lower in
SLE patients than normal controls (P = 0.007, Figure 5c).
Meanwhile, in patients with SLE, IFN-l1i n d u c e dl e s s
secretion of chemokine IL-8 than LPS (P =0 . 0 1 6 ,F i g u r e
5c), but it had the ability to stimulate more IL-8 produc-
tion than medium (P = 0.002, Figure 5c). Thus, through
the above observation, we can acquire the conclusion that
in patients with SLE, IFN-l1 was capable of inducing the
production of chemokines IP-10, MIG and IL-8 which
participate in the pathogenesis of SLE by their special
mechanism.
We next chose to study the dose-response curves for
IFN-l1 inducing IP-10, MIG and IL-8, demonstrating
that in SLE patients, both 10 ng/ml and 50 ng/ml IFN-
l1 had effects on the secretion of IP-10 (P =0 . 0 3 3 ,
0.005, Figure 5d) and stimulated more IP-10 than nor-
mal controls (P = 0.024, 0.047, Figure 5d). IFN-l1d i s -
played its effects at the three different concentration on
MIG secretion with dose-dependent relation (P =0 . 0 4 3 ,
0.016, 0.001, Figure 5e), and the secretion levels of MIG
were higher compared with normal controls (P =0 . 0 3 3 ,
0.029, 0.031, Figure 5e). Compared with other two con-
centration, 10 ng/ml IFN-l1 had the most obvious effect
in the secretion of IL-8, and stimulated more IL-8 secre-
tion than normal controls (P = 0.008, 0.018, Figure 5f).
Table 3 Serum IFN-l1 protein by presence or absence of SLE clinical characteristics
Clinical characteristics Present
n Median (interquartile range)
Absent
n Median (interquartile range)
P-
value
Alopecia 16 297.839 (415.787 to 193.064) 26 305.489 (368.886 to 267.957) NS
Mucosal ulcer 10 307.276 (432.756 to 194.393) 32 300.582 (369.881 to 261.142) NS
Malar rash 26 299.715 (381.168 to 245.771) 16 310.309 (400.762 to 260.412) NS
Fever 10 300.520 (340.477 to 237.890) 32 305.487 (410.534 to 263.343) NS
Chest affection 2 385.455 (440.400 to 330.510) 40 300.522 (371.396 to 260.412) NS
Renal disease 25 330.060 (416.827 to 289.660) 17 270.400 (315.764 to 172.973) 0.0368
Neurological disorder 2 246.952 (298.846 to 195.058) 40 305.488 (400.033 to 261.142) NS
Arthritis 29 330.060 (421.041 to 283.616) 13 265.347 (301.716 to 183.47) 0.0097
Anemia 12 307.276 (422.614 to 211.962) 30 300.582 (368.886 to 260.557) NS
Thrombocytopenia 8 300.520 (330.398 to 192.99) 34 305.488 (409.822 to 262.164) NS
Leucopenia 22 308.144 (411.573 to 245.771) 20 300.520 (360.412 to 260.412) NS
NS, not significant.
Table 2 Correlation between IFN-l1 levels and SLEDAI as
well as laboratory values
Parameter Correlation coefficient (r) P-value
SLEDAI 0.4103 0.007
dsDNA 0.8339 < 0.0001
AnuA 0.598 0.133
Smith 0.798 0.063
rRNP 0.091 0.399
AHA 0.414 0.219
ESR 0.536 0.475
CRP 0.376 0.0141
C3 -0.5863 0.008
C4 0.049 0.093
24-hour urine protein 0.759 0.436
AHA, anti-histone antibody; AnuA, anti-nucleosome antibody; C3, complement
3; C4, complement 4; CRP, C-reactive protein; ds-DNA, anti-double stranded
DNA antibody; ESR, erythrocyte sedimentation rate; rRNP, anti-ribosome
ribonucleoprotein antibody; SLEDAI, SLE disease activity index; Smith, anti-
smith-antibody.
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Page 6 of 12Figure 5 IFN-l1-induced chemokines production by human PBMC and dose-relationship of IFN-l1- induced chemokines by PBMC.
Human PBMC were cultured for 72 h in the presence of recombinant IFN-l1 and supernatants were examined for levels of IP-10, MIG and IL-8
using ELISA. The chemokines’ response to LPS was also examined as a positive control. In SLE patients, IFN-l1-stimulated PBMC displayed higher
levels of chemokines IP-10 (a) and MIG (b) in comparison with positive control LPS. IFN-l1 could induce more generation levels of chemokines
IP-10 (a) and MIG (b) in SLE patients than normal controls, but the secretion levels of IL-8 were lower in SLE patients than normal controls (c).
Meanwhile, in patients with SLE, IFN-l1 induced less secretion of chemokine IL-8 than LPS, but it had the ability to stimulate more IL-8
production than medium (c). Then human PBMC were cultured over different IFN-l1 concentrations for 72 h and supernatants were examined
for IP-10 (d), MIG (e) and IL-8 (f) levels using ELISA. Both 10 ng/ml and 50 ng/ml IFN-l1 had effects on the secretion of IP-10 (P = 0.033, 0.005)
(d). IFN-l1 displayed its effects at the three different concentration on MIG secretion with dose-dependent relation (P = 0.043, 0.016, 0.001) (e).
Compared with other two concentration, 10 ng/ml IFN-l1 had the most obvious effect in the secretion of IL-8 (P = 0.008) (f). *, P < 0.05, **, P <
0.01. means ± s.d. are shown. ELISA, enzyme-linked immunosorbent assay; LPS, lipopolysaccharide; IFNl1, interferon l1; IL-8, interleukin-8; IP-10,
IFN-inducible protein-10; MIG, monokine induced by interferon-g; NC, normal control; PBMC, peripheral blood mononuclear cells; SLE, systemic
lupus erythematosus.
Figure 4 Elevated serum IFN-l1 levels in SLE patients with organ damage.( a)S e r u mI F N - l1 levels exhibited a significant elevation in
patients with renal involvement (n = 25) relative to patients without renal involvement (n = 17) as well as NC; patients in the absence of renal
disorder also displayed higher serum IFN-l1 levels compared with NC. (b) Serum IFN-l1 levels were significantly higher in patients in the
presence of arthritis (n = 29) than patients in the absence of arthritis (n = 13) as well as NC. Each symbol represents an individual patient;
horizontal lines indicate median values. IFNl1, interferon l1; NC, normal control; SLE, systemic lupus erythematosus.
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PBMC
We chose to examine IFN-l1’sa b i l i t yt or e g u l a t ec h e -
mokine response to LPS. In SLE patients, at 100 ng/ml
LPS, only 50 ng/ml IFN-l1 showed a synergistic effect
on the chemokine IP-10 response (P = 0.016, Figure 6a).
With regard to chemokine MIG, different concentration
of IFN-l1 all played an assistant role in the effect of
LPS (P = 0.047, 0.013, 0.038, Figure 6b). Both 10 ng/ml
and 100 ng/ml IFN-l1 manifested this synergistic effect
on the secretion of chemokine IL-8 when 100 ng/ml
LPS were used (P <0 . 0 0 1 ,P = 0.002, Figure 6c). In dif-
ferent culture condition, the generation levels of each
chemokine were higher in SLE patients compared with
normal controls (data not shown).
Discussion
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease affecting multiple organ systems, invol-
ving the skin, joints, heart, lungs, kidneys and central
nervous system (CNS) [34]. Skin involvement, arthritis
and renal disorder are very common manifestations in
patients with SLE. Among them, skin involvement gen-
erally manifests as alopecia, mucosal ulcers or malar
rash. Renal disorders range from asymptomatic hema-
turia or proteinuria to overt nephritic and nephrotic
syndromes, rapidly progressive glomerulonephritis, and
chronic renal failure [35]. So far, the pathogenesis of
SLE has not been illuminated clearly.
Functions of IFN-l1, a type III IFN, include inhibition
of viral infection and proliferation of tumor cells as well
Figure 6 IFN-l1 increased the chemokines response to LPS. Whole PBMC were incubated in the presence of IFN-l1 for 30 minutes before
the addition of LPS at the doses indicated. Cells were then incubated for 72 h before being assessed for levels of IP-10 (a), MIG (b) and IL-8 (c)
in culture supernatants using ELISA. only 50 ng/ml IFN-l1 showed an assistant effect on the chemokine IP-10 secretion (P = 0.016) (a). Different
concentrations of IFN-l1 all played a synergistic role in the effect of LPS (P = 0.047, 0.013, 0.038) (b). Both 10 ng/ml and 100 ng/ml IFN-l1
displayed this synergistic effect on the secretion of chemokine IL-8 (P < 0.001, P = 0.002) (c). *, P < 0.05, **, P < 0.01. means ± s.d. are shown.
ELISA, enzyme-linked immunosorbent assay; IFNl1, interferon l1; IL-8, interleukin-8; IP-10, IFN-inducible protein-10; LPS, lipopolysaccharide; MIG,
monokine induced by interferon-g; NC, normal control; PBMC, peripheral blood mononuclear cells; SLE, systemic lupus erythematosus.
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best of our knowledge, the role of IFN-l1i nt h ep r o -
gression of SLE remains unknown. Therefore, we
hypothesized that IFN-l1 played a role in the pathogen-
esis of autoimmune diseases such as SLE. Real-time
PCR and ELISA assays were used to detect IFN-l1
mRNA expression in PBMC and serum IFN-l1p r o t e i n
levels, respectively. Our initial data showed that IFN-l1
mRNA expression and serum protein levels in patients
with SLE were higher compared with normal controls,
suggesting a role for IFN-l1 in the pathogenesis of SLE.
We were also interested as to whether IFN-l1w a s
associated with disease activity. Under these circum-
stances, SLE patients were divided into active and inac-
tive groups according to SLEDAI scores, and active
groups were defined as a SLEDAI score ≥6 [33]. By ana-
lyzing the data of different groups, finding that IFN-l1
mRNA and protein levels in patients with active disease
were significantly higher compared with patients with
inactive disease together with normal controls. Because
we have known that IFN-l1 can be secreted by PBMC
as well as DC [2,8], meantime, SLE is a kind of autoim-
mune disease characterized by massive abnormal
immune cells response which leads to autoimmune dis-
orders and dysregulation. Therefore, we speculated that
elevated IFN-l1 mRNA and protein levels in patients
with SLE probably were related to abundant and inordi-
nate immune cell response. Thus, our findings implied
that IFN-l1 probably involved in the disease activity of
SLE.
Moreover, we made further efforts to analyze the cor-
relation between serum IFN-l1 protein levels and SLE-
DAI together with several laboratory values, such as
anti-dsDNA, AnuA, Smith, rRNP, AHA antibody, ESR,
CRP, C3, C4 and 24-hour urine protein. Our analysis
results disclosed that significant positive correlations
were found between serum IFN-l1l e v e l sa n dS L E D A I ,
anti-ds-DNA antibody and CRP, and there was also a
negative relationship between IFN-l1 levels and C3.
CRP is an acute-phase protein known as a biomarker
for inflammation, and has been traditionally used to
detect and predict the outcome of infections, inflamma-
tory, necrotic processes as well as monitor clinical dis-
ease activity together with efficacy of treatment [37,38].
Reports have displayed that CRP levels above 60 mg/l in
febrile SLE patients without serositis almost always indi-
cate infection; whereas in SLE alone, CRP levels are only
moderately raised even in patients with very active dis-
ease [39]. In our study, the highest CRP value was 26.9
mg/l, and most CRP values were between 0 to 10 mg/l;
therefore, in this study, CRP was a biomarker not indi-
cating infection but monitoring disease activity. C3, one
of complement components, participates in elimination
of immune complexes through combination with
immunoglobulin to disturb interaction of crystallizable
fragment in space, and its reduction indicates disease
activity. Therefore, by these results, we obtained the
conclusion that IFN-l1 may influence disease activity in
SLE for a second time.
In patients with SLE, various manifestations make
patients feel pain both physically and mentally. The
most common clinical manifestations were arthritis
(67%), malar rash (66%), nephritis (55%), and central
nervous system (CNS) disease (27%) [40]. In conse-
quence, we also assessed the correlation between IFN-
l1 and disease manifestations in patients with SLE;
however, we did not distinguish the relationships among
serum IFN-l1 protein levels and alopecia, mucosal
ulcer, malar rash, fever, chest affection, neurological dis-
order, anemia, thrombocytopenia and leucopenia. We
discriminated that serum IFN-l1 protein expression was
significantly higher in patients with renal involvement
and arthritis in comparison with patients without the
above-mentioned disease manifestation as well as nor-
mal controls. In this case, we had evidence to infer that
IFN-l1 may involve in development of renal involve-
ment and arthritis in SLE. Although our research did
not observe an association between IFN-l1p r o t e i n
expression and other clinical manifestations, maybe this
result was related to the limitation of small samples.
Since we had come to a decision that IFN-l1m a y
participate in the pathogenesis of SLE, and has associa-
tion with disease activity as well as progression of arthri-
tis and renal disorder, we were interested in the
mechanism by which IFN-l1 played an important part
in the development of SLE.
Chemokines are a group of molecules which have the
ability to direct leucocytes to inflammatory sites to take
part in immune response, influence maturation of kinds
of immune cells, such as DC, T cell and stimulate
monocytes, NK cells as well as T cell migration together
with accommodate adhesion molecule expansion
[20-22]. Chemokines IP-10, MIG and IL-8 are from the
CXC family, and play an important role in the chronic
inflammatory immune responses by recruiting leuko-
cytes to inflammatory sites [25-27].
Besides, recent studies have reported that serum
inflammatory chemokines IP-10 and MIG levels were
elevated in SLE patients compared with normal controls.
In addition, they had a positive relation with SLEDAI.
Furthermore, in SLE patients with renal involvement,
IP-10 and IL-8 levels were positively correlated with dis-
ease activity [29]. Beyond that, IP-10, IL-8 and MIG
levels in cerebrospinal fluid (CSF) were significantly
increased in neuropsychiatric SLE (NPSLE) patients
compared with those with non-NPSLE and nonautoim-
mune diseases [41]. Another research team had calcu-
lated chemokine scores using several chemokines
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finding that chemokine scores were significantly elevated
in SLE patients versus RA patients and healthy donors
and were correlated positively with SLEDAI scores and
negatively with C3 levels. Compared with patients with-
out lupus nephritis and those with inactive lupus
nephritis, chemokine scores were increased in patients
with active lupus nephritis. Elevated chemokine scores
were also associated with the presence of cumulative
o r g a nd a m a g ea n dt h eo c c u r r e n c eo fa n t i - S mo ra n t i -
RNP autoantibodies [42]. Thus, elevation of chemokines
could promote immune cells to migrate to inflammation
site and take part in progression of inflammation by
their cytotoxic effect or secretory inflammatory mediator
in autoimmune diseases including SLE.
What is more, Pekarek V [36] had reported that IFN-
l1 could elevate mRNA levels of MIG, IP-10 and ‘IFN-
gamma inducible T-cell alpha chemoattractant’ (I-TAC/
CXCL11) from normal human PBMC. As a result, for
exploring the function mechanism of IFN-l1 in SLE, we
detected the ability of IFN-l1 to induce PBMC to secret
MIG, IP-10 and IL-8 in patients with SLE, recognizing
that in patients with SLE, IFN-l1 had the ability to
induce secretion of IP-10, MIG and IL-8. Meanwhile, it
had its effects at three different concentrations with
MIG levels increasing dose-dependently. Moreover, sev-
eral concentrations of IFN-l1 had a synergistic role with
LPS in the production of chemokines IP-10, MIG and
IL-8. Consequently, we deduced that IFN-l1 presumably
took effect in SLE by stimulating overexpression of che-
mokines IP-10, IL-8 and MIG associated with pathogen-
esis of SLE. In this case, it is reasonable to infer that
after producing by a mount of abnormal PBMC, IFN-l1
then stimulated PBMC to secret chemokines which
could participate in the development of SLE through
several different mechanisms. Therefore, this condition
becomes a sort of vicious circle which is harmful to the
disease situation of patients with SLE.
We know that bacterial infections may serve as envir-
onmental triggers for the development or exacerbation
of SLE in genetically predisposed individuals [43], and
that bacterial LPS plays an important role in the patho-
genesis of SLE, such as, it could aggravate disease devel-
opment by activating proliferation of B cells, production
of autoantibodies and proinflammatory cytokines
[44,45]. Moreover, Pawar RD et al. [46] reported that in
nephritic MRL
lpr/lpr mice, transient exposure to bacter-
ial cell wall components LPS increased splenomegaly,
production of DNA autoantibodies, serum IL-6, IL-12 as
well as tumor necrosis factor (TNF) levels, and aggra-
vated lupus nephritis (LN), which was a major complica-
tion of SLE and associated with high rates of morbidity
[43]. In our study, we observed that there was a synergic
effect of IFN-l1 and LPS on the chemokines expression.
Thus, we inferred that, except for the various effect of
single LPS on the development of SLE and LN, together
with the synergic effect of IFN-l1 and LPS on the che-
mokines secretion, they could play a powerful effect on
the inflammation process of SLE, and promote the dis-
ease aggravation in patients with SLE, especially with
LN. Thus, we supposed that not only did IFN-l1p a r t i -
cipate in the renal involvement but also it played the
pathogenic role by combining with the effect of LPS.
Therefore, for patients with SLE accompanying LN, they
should avoid bacterial infections in order to prevent dis-
ease progression.
At the same time, it is interesting to compare the role
of different types of IFN in the pathogenesis of SLE. As
is well known, Type I IFN (IFN-a,I F N - b)a n dT y p eI I
IFN (IFN-g) are classic interferons, and play an impor-
tant role in the pathogenesis of SLE. Some reports have
displayed that compared to healthy and unrelated indivi-
duals, higher activity of IFN-a was found in the serum
of both SLE patients and healthy relatives, and it was
associated with autoantibodies to RNA-binding proteins
and double-stranded DNA [47]. Levels of Type I IFN
correlated with the presence of cutaneous manifesta-
tions, and positively with the SLEDAI score and anti-
dsDNA levels and inversely with C3 levels [3]. Expres-
sion of IFN-g was significantly increased in the PBMC
of SLE patients compared with healthy controls [5], and
its expression in urinary sediment was significantly
higher in the active lupus nephritis than in inactive SLE
and previous renal involvement. Among the SLE
patients, there was a close correlation between expres-
sion of IFN-g and the SLEDAI score [6]. Therefore,
compared with the above mentioned research findings,
we found that there was a lot of similarity with respect
to the role of IFN-l1 and Type I IFN as well as Type II
IFN in the pathogenesis of SLE.
However, we must acknowledge some limitations of
this study. The sample size of our study was small with
42 lupus patients and 25 controls, because a small sam-
ple size has a greater probability that the observation
may happen to be especially good or bad, and statistical
tests usually require a larger sample size to justify that
t h ee f f e c td i dn o th a p p e nb yc h a n c ea l o n e .M o r e o v e r ,
owing to its cross-sectional design, it is difficult to
establish the exact and definite causal relationships
except association between IFN-l1 and development of
SLE from the collected data. Another disadvantage of
such a study is that it can only identify a high propor-
tion of prevalent cases of long duration. Patients who
die soon or who recover quickly are less likely to be
identified as diseased.
Meanwhile, because the mechanism of IFN-l1i nt h e
pathogenesis of SLE is very complicated, we hope
there will be a lot of new findings about the role of
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near future.
In conclusion, this preliminary study demonstrated
that IFN-l1 perhaps played a part in the pathogenesis
of SLE and had a positive association with disease
activity. Meanwhile, it was likely to refer to the devel-
opment of renal disease as well as arthritis in SLE.
Furthermore, we observed that IFN-l1 probably played
an important role in the pathogenesis of SLE by indu-
cing production of chemokines IP-10, MIG and IL-8
which attended the progression of SLE. The present
study of IFN-l1 may offer new insight for future stu-
dies on pathogenesis of SLE and novel research targets
for SLE therapy.
Conclusions
The present study suggests that IFN-l1, as one kind of
interferon, may participate in the pathogenesis of SLE
by modulating the expression of chemokines IP-10,
MIG and IL-8, and IFN-l1 may be related to disease
activity in SLE. The findings of such studies will provide
new insight into the pathogenesis as well as therapy of
SLE, and will shed new light on the dysregulation of the
immune system in autoimmune diseases.
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